Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes

Rhea-AI Filing Summary

Sana Biotechnology, Inc. officer Susan D. Wyrick reported equity transactions involving restricted stock units and common shares. On March 2, 2026, 1,525 restricted stock units were exercised into 1,525 shares of common stock at $0.00 per share, increasing her direct holdings to 187,408 common shares. On March 3, 2026, 491 common shares were disposed of at $3.91 per share to satisfy tax withholding obligations, leaving 186,917 common shares directly owned. Each restricted stock unit represents a right to receive one share of Sana common stock, vesting in four annual 25% installments on March 2 of 2024, 2025, 2026 and 2027, subject to continued service.

Insider Trade Summary

1,525 shares exercised/converted

Mixed 3 txns

Insider Wyrick Susan D.

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	491	$3.91	$2K
Exercise	Restricted Stock Units	1,525	$0.00	--
Exercise	Common Stock	1,525	$0.00	--

Holdings After Transaction: Common Stock — 186,917 shares (Direct); Restricted Stock Units — 1,525 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wyrick Susan D.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		M		1,525	A	$0.00	187,408	D
Common Stock	03/03/2026		F		491	D	$3.91	186,917	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/02/2026		M			1,525	(2)	(2)	Common Stock	1,525	$0.00	1,525	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

2. The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

Remarks:

SVP, Finance and Accounting and Principal Accounting Officer

	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Susan D. Wyrick report for Sana Biotechnology (SANA)?

Susan D. Wyrick reported exercising 1,525 restricted stock units into 1,525 Sana common shares and disposing of 491 common shares for tax withholding. These transactions are routine equity compensation events reflecting vesting and related tax payments rather than open-market buying or selling activity.

How many Sana Biotechnology (SANA) shares does Susan D. Wyrick own after the reported Form 4 transactions?

After the reported transactions, Susan D. Wyrick directly owns 186,917 shares of Sana common stock. This follows the exercise of 1,525 restricted stock units into common shares and the disposition of 491 shares used to cover associated tax withholding obligations.

What was the nature of the 491-share disposition reported by Susan D. Wyrick at Sana Biotechnology (SANA)?

The 491-share disposition was for tax withholding, not an open-market sale. Shares of Sana common stock were delivered at $3.91 per share to satisfy exercise price or tax liabilities triggered by equity award vesting and restricted stock unit exercises.

How do Susan D. Wyrick’s restricted stock units in Sana Biotechnology (SANA) vest over time?

Each restricted stock unit converts into one Sana common share and vests in four equal 25% installments on March 2 of 2024, 2025, 2026, and 2027. Vesting requires Ms. Wyrick to remain in continuous service with Sana through each applicable vesting date.

What was the exercise price for the restricted stock units reported by Susan D. Wyrick at Sana Biotechnology (SANA)?

The restricted stock units were exercised at an effective price of $0.00 per share. Each unit represents a contingent right to receive one share of Sana common stock upon vesting and settlement, consistent with typical restricted stock unit award structures.